What a nice way to kick off my week. Sold 22k shares in pre market between $6.88. - $7.40, truly blessed. Now will all of the proceeds into OPK and CEMP
Stock halted! We will open above $4 60
Exelixis will be filing with U.S. and European regulators to ask to sell Cometriq for kidney cancer based on this data. Analysts think that Novartis sells about $400 million worth of Torisel in kidney cancer (that drug is approved for other cancers as well), so it is possible that an approval could eventually result in hundreds of millions of dollars in sales.
Dr. Morrissey continued, “Delivering these top-line results for METEOR is one of multiple clinical development and regulatory milestones that we have planned for this year. These milestones collectively have the potential to significantly enhance the opportunities before us and bring value to the multiple stakeholders we serve. We look forward to sharing the detailed results of METEOR with the oncology community at an upcoming medical conference, and we thank all of the patients, families, investigators, and clinical staff who made the trial possi
- Study Met Primary Endpoint of Significantly Improving Progression-Free Survival -
- Cabozantinib Reduced the Risk of Disease Progression or Death by 42%; Hazard Ratio = 0.58, (p
Interesting point of view. I have seen what happened (the run up) take place so many times with these bios, that it's not funny, that why I got out at 4.11. I have rinsed and washed this stock three times this year for a very, very nice profit. Been loading up on OPK and EXEL,which will run and then settle back down. Rinse and wash has been my strategy this year.
PS this is a very informative board and more importantly a great stock. I will pick up some cheap share today and hold them for the next run up.
Where do you think ARIA will be in the next 30 to 60 days? Back to $10? The next ER should be strong!
Small-cap biopharmaceutical company Exelixis (NASDAQ:EXEL) sent a simple message to investors this past week: "Wait for it... No, seriously, wait for it."
Exelixis' holding pattern
The second-half of 2015 was supposed to bring a number of catalysts for Exelixis and its shareholders. One was the Food and Drug Administration's expected decision on approval of the combination of Exelixis' cobimetinib and Roche's Zelboraf as a treatment for BRAF V600 mutation-positive metastatic melanoma. The combination therapy garnered a priority review from the FDA, shortening the review process from the standard 10 months to six months and carrying a PDUFA date (i.e., an FDA decision date) of Aug. 11, 2015.......